| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ltxA |
| Uniprot No | P16462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 721-1055aa |
| 氨基酸序列 | IGSTLRDKFYGSKFNDVFHGHDGDDLIYGYDGDDRLYGDNGNDEIHGGQGNDKLYGGAGNDRLFGEYGNNYLDGGEGDDHLEGGNGSDILRGGSGNDKLFGNQGDDLLDGGEGDDQLAGGEGNDIYVYRKEYGHHTITEHSGDKDKLSLANINLKDVSFERNGNDLLLKTNNRTAVTFKGWFSKPNSSAGLDEYQRKLLEYAPEKDRARLKRQFELQRGKVDKSLNNKVEEIIGKDGERITSQDIDNLFDKSGNKKTISPQELAGLIKNKGKSSSLMSSSRSSSMLTQKSGLSNDISRIISATSGFGSSGKALSASPLQTNNNFNSYANSLATTA |
| 预测分子量 | 38.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于 **LtxA(Leukotoxin A)重组蛋白** 的参考文献示例(内容基于领域常见研究方向整合，非真实文献)：
---
1. **标题**：*"Recombinant Production and Cytotoxic Characterization of LtxA from Aggregatibacter actinomycetemcomitans"*
**作者**：Mintz KP, et al.
**摘要**：研究利用大肠杆菌表达系统成功克隆并纯化重组LtxA蛋白，证实其对人类免疫细胞(如中性粒细胞)的特异性细胞毒性，并探讨了其与宿主细胞膜胆固醇的相互作用机制。
2. **标题**：*"Immunomodulatory Effects of Purified LtxA in Periodontal Disease Models"*
**作者**：Johansson A, et al.
**摘要**：通过体外实验和小鼠模型，证明重组LtxA可诱导促炎因子释放，并揭示其在牙周炎病理过程中通过破坏白细胞线粒体功能加剧组织损伤的作用。
3. **标题**：*"Structural Insights into LtxA Pore-Forming Mechanism by Cryo-EM Analysis"*
**作者**：Balashova NV, et al.
**摘要**：利用冷冻电镜解析重组LtxA的寡聚化结构，阐明其形成跨膜孔道的分子机制，为开发靶向LtxA的抑制剂提供理论基础。
4. **标题**：*"Recombinant LtxA as a Vaccine Candidate Against A. actinomycetemcomitans Infection"*
**作者**：Taichman NS, et al.
**摘要**：评估重组LtxA蛋白的免疫原性，发现其在小鼠模型中可诱导中和抗体，显著降低细菌定植和牙槽骨吸收，提示其作为疫苗组分的潜力。
---
**注**：以上文献名为示例性整合，具体研究需通过学术数据库(如PubMed、Web of Science)以关键词“LtxA recombinant”“Leukotoxin A expression”检索真实文献。
**Background of LtxA Recombinant Protein**
LtxA (leukotoxin A) is a cytotoxic protein primarily produced by *Aggregatibacter actinomycetemcomitans*, a Gram-negative bacterium associated with periodontal diseases and systemic infections. This toxin belongs to the repeats-in-toxin (RTX) family, characterized by conserved glycine- and aspartate-rich repeats. LtxA specifically targets immune cells, such as neutrophils, monocytes, and lymphocytes, by binding to the β₂ integrin lymphocyte function-associated antigen-1 (LFA-1) on host cell membranes. This interaction triggers pore formation, calcium influx, and apoptosis, enabling the bacterium to evade immune responses and persist in host tissues.
Recombinant LtxA is generated through genetic engineering, often using *Escherichia coli* expression systems, to produce purified toxin variants for research and therapeutic applications. Its recombinant form allows precise control over structural and functional properties, facilitating studies on host-pathogen interactions, immune evasion mechanisms, and cellular signaling pathways. Additionally, modified LtxA variants with attenuated toxicity are explored for vaccine development or targeted cancer therapies, leveraging its specificity for LFA-1-expressing cells.
Research on LtxA also contributes to understanding RTX toxin biology, including secretion mechanisms, host cell specificity, and pore-forming dynamics. Its role in periodontal disease pathogenesis underscores its clinical relevance, driving efforts to develop diagnostic tools or anti-virulence strategies. Overall, recombinant LtxA serves as a critical tool for dissecting bacterial toxicity and advancing biomedical interventions.
×
